Navigation Links
Harvard University: Big Pharma is Corrupted; CBCD Sees Connection between Corruption & Productivity Crisis in R&D
Date:11/1/2013

Rochester, NY (PRWEB) November 01, 2013

Big Pharma suffers from institutional corruption according to Harvard University researchers (1). They came to this conclusion after examining Pharma’s practices and policies in 5 different categories: systemic problems, medical research, medical knowledge and practice, marketing, and patient advocacy organizations. The CBCD believes this institutional corruption is a result of the productivity crisis in pharmaceutical R&D.

What is institutional corruption?

According to Marc A. Rodwin, one of the lead researchers, institutional corruption is “widespread or systemic practices, usually legal, that undermine an institution's objectives or integrity. Institutional corruption displaces some goals and compromises the attainment of others (2).”

An example of systemic corruption, (corruption of the entire system, or way of doing things) is Big Pharma’s funding of political campaigns, selectively providing information to legislators, subsidizing their work, and targeting campaign contributions to influential legislators and allies (1). Another example of a systemic problem is the fact that “Firms have strong financial incentives to develop so-called me-too drugs - products which are minor variations of existing drugs - and to heavily market them in ways that exaggerate their benefits and fail to reveal their full risks (1).”

The Harvard researchers found that Big Pharma manipulates physicians across America to achieve their financial goals. They wrote that “widespread practices in the medical and pharmaceutical industries can lead to doctors who are psychologically, financially, or intellectually dependent on drug companies (1).” In other words, Pharma turned these doctors into their agents. This is a phenomenon which has “resulted in…Doctors who take such misleading information at face value (and) prescribe drugs that are often unnecessary, harmful to patients, or more costly than equivalent medications (1).”

In short, the Harvard researchers “uncovered how pharmaceutical marketing …distorts medical practice… (1).”

When normal people become corrupted, it is usually due to extreme pressure. For example, when someone holds a gun to the head of one’s child, or when one is bankrupt and must still purchase food for one’s family…then one may be driven to extreme acts. The same holds true for Big Pharma. The productivity crisis is driving Pharma to extreme measures. These extreme measures were labeled by researchers as ‘institutional corruption.’

For more information on the productivity crisis in pharmaceutical R&D, please visit:

http://www.prweb.com/releases/2013/10/prweb11232090.htm

and

http://www.prweb.com/releases/2013/10/prweb11273236.htm

The CBCD invites pharmaceutical executives to contact the Center to discuss forward thinking strategies that can help reduce corruption while maximizing profits.

We invite the media to contact us for interviews at: info (at)buy-gene-eden(dot)com or phone 585-250-9999.

###

References:
(1)    http://www.law.harvard.edu/news/2013/10/25_edmond-j-safra-center-for-ethics-fellows-jlme.html
(2)    http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2298140
(3)    http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101

The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments.

The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between foreign DNA and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11290033.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Harvard researchers, pharma experts offer recommendations to expand access to clinical trial data
2. Genia Technologies, Columbia University, and Harvard University Awarded $5.25 Million Grant from NIH to Accelerate the Development of NanoTag DNA Sequencing Technology
3. Jeffrey Epstein, Science Financier, Changes the Course of Evolution at Harvard
4. Director of Proteomics at the Broad Institute of MIT and Harvard, Steven Carr, to Deliver Pittcon 2014 Wallace H. Coulter Plenary Lecture
5. Life Technologies Signs License and Collaborative Stem Cell Research Agreement with Harvard University
6. Harvard Wyss Institutes Lung-on-a-Chip wins prize for potentially reducing need for animal testing
7. Harvards Wyss Institute team creates versatile 3d nanostructures using DNA bricks
8. Harvards Wyss Institute models a human disease in an organ-on-a-chip
9. UMass Amherst, Harvard experts say better systems needed for medical device cybersecurity
10. Harvards Wyss Institute creates living human gut-on-a-chip
11. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):